Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: A clinical appraisal

Heart

Volumn 97, Issue 22, 2011, Pages 1828-1833

  Perrone Filardi, Pasquale ^a   Paolillo, Stefania ^a   Dellegrottaglie, Santo ^a   Gargiulo, Paola ^a   Savarese, Gianluigi ^a   Marciano, Caterina ^a   Casaretti, Laura ^a   Cecere, Milena ^a   Musella, Francesca ^a   Pirozzi, Elisabetta ^a   Parente, Antonio ^a   Cuocolo, Alberto ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMIODARONE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; LUGOL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOPROLOL; NORADRENALIN; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC CARDIOMYOPATHY; MORTALITY; MYOCARDIAL PERFUSION IMAGING; NORADRENALIN UPTAKE; PATHOPHYSIOLOGY; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN DEATH; SYMPATHETIC TONE; SYSTOLIC DYSFUNCTION;

3-IODOBENZYLGUANIDINE; DISEASE PROGRESSION; HEART FAILURE; HUMANS; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; SYMPATHETIC NERVOUS SYSTEM;

EID: 80055113188     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300343     Document Type: Review

References (32)

1. Carriò I, Cowie MR, Yamazaki J, et al. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging 2010;3:92-100.
2. Authors/Task Force Members, Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.
3. Haider N, Balinga RR, Chandrashekhar Y, et al. Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. JACC Cardiovasc Imaging 2010;3:71-5.
4. Flotats A, Carrió I, Agostini D, et al. EANM Cardiovascular Committee; European Council of Nuclear Cardiology. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802-12.
5. Bax JJ, Kraft O, Buxton AE, et al. 123I-MIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.
6. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31. (Pubitemid 36503797)
7. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;15:2769-77.
8. Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426-35.
9. Katoh S, Shishido T, Kutsuzawa D, et al. Iodine-123- metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med 2010;24:679-86.
10. Jacobson AF, Senior R, Cerqueira MD, et al. ADMIRE-HF Investigators. Myocardial Iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
11. Tsukamoto T, Morita K, Naya M, et al. Decreased myocardial beta-adrenergic receptor density in relation to increased sympathetic tone in patients with nonischemic cardiomyopathy. J Nucl Med 2007;48:1777-82. (Pubitemid 350099321)
12. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
13. Verberne HJ, Brewster LM, Somsen GA, et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29:1147-59. (Pubitemid 351844881)
14. Kasama S, Toyama T, Sumino H, et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011;97:20-6.
15. De Marco T, Dae M, Yuen-Green MS, et al. Iodine-123- metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart: evidence for late reinnervation. J Am Coll Cardiol 1995;25:927-31.
16. Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217-23. (Pubitemid 29077081)
17. Gerson MC, Craft LL, McGuire N, et al. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123-metaiodobenzylguanidine. J Nucl Cardiol 2002;9:608-15. (Pubitemid 36050207)
18. Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884-90. (Pubitemid 39663398)
19. Kasama S, Toyama T, Kumakura H, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-7. (Pubitemid 40278963)
20. Kasama S, Toyama T, Kumakura H, et al. Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81. (Pubitemid 36223322)
21. Toyama T, Hoshizaki H, Seki R, et al. Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with beta-blocker therapy. J Nucl Cardiol 2004;11:134-41. (Pubitemid 38949907)
22. Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC Cardiovasc Imaging 2010;3:64-70.
23. Erol-Yilmaz A, Verberne HJ, Schrama TA, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 2005;28:304-10. (Pubitemid 40613059)
24. Gould PA, Kong G, Kalff V, et al. Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace 2007;9:751-6. (Pubitemid 47371648)
25. Burri H, Sunthorn H, Somsen A, et al. Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace 2008;10:374-8. (Pubitemid 351773736)
26. Kasama S, Toyama T, Sumino H, et al. Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. Heart 2011;97:817-22.
27. Kasama S, Toyama T, Sumino H, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008;49:907-14. (Pubitemid 351793431)
28. Shan K, Bick RJ, Poindexter BJ, et al. Altered adrenergic receptor density in myocardial hibernation in humans: a possible mechanism of depressed myocardial function. Circulation 2000;102:2599-606.
29. Perrone-Filardi P, Pace L, Prastaro M, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation 1996;94:2712-19. (Pubitemid 26411733)
30. Indolfi C, Piscione F, Perrone-Filardi P, et al. Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in patients with hibernating myocardium. Am Heart J 1996;132:542-9. (Pubitemid 26347757)
31. Pace L, Perrone Filardi P, Mainenti PP, et al. Identification of viable myocardium in patients with chronic coronary artery disease using rest-redistribution thallium-201 tomography: optimal image analysis. J Nucl Med 1998;39:1869-74. (Pubitemid 28518884)
32. Kobayashi M, Izawa H, Cheng XW, et al. Dobutamine stress testing as a diagnostic tool for evaluation of myocardial contractile reserve in asymptomatic or mildly symptomatic patients with dilated cardiomyopathy. JACC Cardiovasc Imaging 2008;1:718-26.